BSECompany Update31 Oct 2026 · 31 Oct 2026, 08:27 pm

Statement of Deviation and Variation w.r.t. QIP

Neogen Chemicals Ltd · 542665

✦ AI SummaryFundraise

Neogen Chemicals Ltd has filed a statement of deviation and variation for the Qualified Institutional Placement (QIP) issue of equity shares, stating that the funds raised have been utilized as per the original objects and purposes, with no deviation or variation.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Neogen Chemicals Ltd - 542665 - Statement Of Deviation And Variation

Attachments (1)

📄

a86054e5-4474-498f-8dac-42572cef7f9d.pdf

pdf

Download →
View document text
':,( .~ .. NEOGEN~ ~~ CHEMICALS LTD. NEOGEN® CHEMICALS LTD. Quarterly Reporting for Qualified Institutional Placement Issue of Equity Shares under Regulation 32 of Listing Regulation. Statement of Deviation L Variation in utilisation of funds raised Name of listed entity Neogen Chemicals Limited SCRIP Code 542665 NSE Symbol NEOGEN MSEl Symbol NOTLISTED ISIN INE136S01016 No. of times funds raised 1 Mode of Fund Raising Qualified Institutional Placement of Equity Shares Date of Raising Funds 16-09-2026 Amount Raised (Rs. In crores) 600 Report filed for Quarter ended 30-09-2026 Monitoring Agency Applicable Monitoring Agency Name, if applicable CRISIL Ratings Limited Is there a Deviation I Variation in use of funds raised NO If yes, whether the same is pursuant to change in terms of a contract or Not Applicable objects, which was approved by the shareholders If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation/ Variation Not Applicable Comments of the Audit Committee after review No Comments of the auditors, if any No Objects for which funds have been raised and where there has been a See table below deviation, in the following table (Amount in Crores) Original Object Modified Original Modified Funds Amount of Remarks if any Object, if Allocation allocation, if Utilised Deviation/Variation for any any during the the quarter according to quarter applicable object Repayment/ pre-payment, in full or part, of NO 265 Not 3.57 0 certain borrowings availed by our Applicable Company Funding our long-term working capital NO 175 163.07 0 requirements General corporate purposes* NO 140 63.71 0 *The amount utilized for general corporate purpose did not exceed 25% of the Gross proceeds. 580 230.35 0 Note: Out of the total gross proceeds of Rs. 600 crore, estimated funds to be utilised towards issue related expenses (includes fees, commission and expenses of the Issue) is Rs. 20 crore of which Rs.18.52 crore was utilised towards issue related expenses during the quarter ended September 30, 2026. Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc Name of Signatory Gopikrishnan Sarathy rv/" ~ ~~ Designation Chief Financial Officer , ~( ~ ....... u::: ;~,t Date 31-10-2026 r7i\\ I• tr- 1 Registered Office: 1002, Dev Corpora, Opp.Cadbury Junction. E : sales@neogenchem.com T : +91 22 2549 7300 Khopat, Eastern Express Highway, Thane (W) 400 601, India W : www.neogenchem.com F : +91 22 2549 7399 CIN No. L24200MH1989PLC050919